Evidence map›Paper›PMID 42255245›Full record

ArticleFrontiers in oncology2026

Feasibility of artificial intelligence-based rapid on-site evaluation for the diagnosis of pulmonary disease.

Yuxian Chen, Chengcheng Du, Pengchen Gu, Chunhai Li, Hong Meng, Fanlei Kong

Abstract read
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yuxian ChenDepartment of Radiology, Qilu Hospital of Shandong University, Jinan, China.
Chengcheng DuDepartment of Radiology, Qilu Hospital of Shandong University, Jinan, China.
Pengchen GuShanghai Aitrox Technology Corporation Limited, Shanghai, China.
Chunhai LiDepartment of Radiology, Qilu Hospital of Shandong University, Jinan, China.
Hong MengDepartment of Radiology, Qilu Hospital of Shandong University, Jinan, China.
Fanlei KongDepartment of Radiology, Qilu Hospital of Shandong University, Jinan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: This study aimed to investigate the clinical feasibility of artificial intelligence-rapid on-site evaluation (AI-ROSE) based on exfoliated cell blotting from percutaneous puncture biopsy specimens for diagnosing pulmonary lesions and to provide a reference for intraoperative rapid diagnosis. Methods: A total of 266 patients with pulmonary lesions who underwent computed tomography (CT)-guided percutaneous core needle biopsy between June 11 and November 27, 2024, were enrolled. Exfoliated cell prints from biopsy specimens were stained with Diff-Quik, followed by diagnosis using AI-ROSE. Using the final histopathological diagnosis as the standard, the accuracy, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of AI-ROSE and conventional cytological diagnoses were compared. The consistency between the methods and histopathological diagnosis was analyzed. The diagnostic times for AI-ROSE, cytology, and histopathology were recorded and compared. Postoperative complications were documented, and the correlation between lesion characteristics and complications was analyzed. Results: Compared with histopathological results, AI-ROSE achieved a sensitivity of 95.67%, specificity of 79.31%, diagnostic accuracy of 92.11%, PPV of 94.31%, and NPV of 83.64% in diagnosing pulmonary lesions, with good consistency (κ = 0.764, P < 0.001). No significant difference in the AI-ROSE diagnostic accuracy was observed among the different pathological types (P > 0.05). Conventional cytological diagnosis showed a sensitivity of 87.50%, specificity of 85.71%, and accuracy of 87.10%, with lower consistency and histopathology (κ = 0.665, P < 0.001) than those of AI-ROSE. The mean diagnostic time of AI-ROSE was 254.60 ± 13.88 s, which was significantly shorter than that of cytology (1.48 ± 0.86 days) and histopathology (2.37 ± 1.42 days). The overall incidence of postoperative complications was 22.93%, including pneumothorax (12.78 %) and needle tract bleeding/mild hemoptysis (9.77%), with no fatal complications. A smaller nodule volume was associated with a higher risk of puncture bleeding (P = 0.004), whereas lesion size and puncture path length were not significantly correlated with pneumothorax risk (P > 0.05). Discussion: AI-ROSE enables rapid intraoperative diagnosis of pulmonary lesions in percutaneous biopsy with high diagnostic performance and consistency with histopathological results, demonstrating its favorable value for clinical application and popularization.

Indexed as

artificial intelligenceexfoliated cell printpercutaneous core needle biopsypulmonary lesionsrapid on-site evaluation

Identifiers

PMID42255245
PMCPMC13233213

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.